As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This comment letter, submitted by ACRO to the FDA in 2025 on Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products, can be found below.